Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

被引:3
作者
Elshaer, Amani [1 ]
Chascsa, David M. H. [2 ,3 ]
Lizaola-Mayo, Blanca C. [2 ,3 ]
机构
[1] Mayo Clin, Dept Internal Med, Scottsdale, AZ 85054 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ 85054 USA
[3] Mayo Clin, Transplant Ctr, Dept Med, Scottsdale, AZ 85054 USA
来源
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词
metabolic-associated steatotic liver disease; fibrosis; cirrhosis; obesity; weight loss; lifestyle modification; pharmacotherapy; bariatric surgery; LIFE-STYLE MODIFICATION; CLINICAL-PRACTICE UPDATE; GLUCAGON-LIKE PEPTIDE-1; CORONARY-HEART-DISEASE; FATTY LIVER; BARIATRIC SURGERY; INSULIN-RESISTANCE; WEIGHT-LOSS; NONALCOHOLIC STEATOHEPATITIS; AMERICAN ASSOCIATION;
D O I
10.3390/life14070844
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?
    Gastaldelli, Amalia
    Newsome, Philip N.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
  • [32] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [33] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [34] Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
    Zhou Da
    Fan Jiangao
    中华医学杂志英文版, 2024, 137 (22)
  • [35] Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
    Zhou, Da
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2024, 137 (22) : 2687 - 2696
  • [36] Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
    Hutchison, Alan L.
    Tavaglione, Federica
    Romeo, Stefano
    Charlton, Michael
    JOURNAL OF HEPATOLOGY, 2023, 79 (06) : 1524 - 1541
  • [37] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [38] Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights
    Aggeletopoulou, Ioanna
    Tsounis, Efthymios P.
    Triantos, Christos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [39] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [40] Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
    Li, Yamei
    Qi, Ping
    Song, Si -Yuan
    Wang, Yiping
    Wang, Hailian
    Cao, Peng
    Liu, Yu 'e
    Wang, Yi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 174